

Revive Therapeutics

12:50 26 Oct 2020

Revive Therapeutics commits to 10 sites for Phase 3 coronavirus trial of bucillamine

Revive Therapeutics Ltd (CSE:RVV) (OTCMKTS:RVVTF) announced Monday that it has committed to 10 clinical sites in the US for its Phase 3 trial of bucillamine in mild-to-moderate cases of the coronavirus and expects more than 200 patients to complete the study by the end of the year.

The study is testing two dosage levels of bucillamine, and an interim analysis of the initial patients will determine the better performing bucillamine dose arm for the remainder of the trial and future complementary studies of more severe cases.

"We are one of a few life sciences companies evaluating an investigational drug in a Phase 3 clinical trial for COVID-19 and with the rising prevalence of cases throughout the US, we are confident that our targets will be achieved to support the potential FDA approval and commercialization of bucillamine for the treatment of the virus," CEO Michael Frank said in a statement.

READ: Revive Therapeutics signs supply agreement with Havn Life Sciences to source psychedelic compounds for use in future studies

The trial, titled, "A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients with Mild-Moderate COVID-19", will enroll as many as 1,000 patients that will be randomized 1:1:1 to receive bucillamine 100 mg three times a day (TID), bucillamine 200 mg TID or placebo TID for up to 14 days.

The company also pointed to the recent publication of research in the October 2020 issue of Clinical Immunology highlighting the potential of N-acetyl-cysteine (NAC) in the treatment of COVID-19. NAC has been shown to significantly attenuate clinical symptoms in respiratory viral infections in animals and humans, primarily via donation of thiols to increase antioxidant activity of cellular glutathione. Revive said the research serves as further validation for bucillamine as a potential COVID-19 treatment.

Bucillamine, with its well-established safety record in more than 30 years of use in the treatment of rheumatoid arthritis, has been shown to be 16 times more potent as a thiol donor in vivo than NAC. Bucillamine also has the potential to lessen the destructive consequences of more advanced SARS-CoV-2 infections, the company said.

The company added that it is not making any express or implied claims that its product has the ability to eliminate or cure the coronavirus at this time.


Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Price: 0.6

Market Cap: \$142.07 m

1 Year Share Price Graph



January 2020 July 2020 January 2021

Share Information

Code: RVV

Listing: CSE

52 week High Low
0.92 0.035

Sector: Pharma & Biotech

Website: www.revivetherapeutics.com

Company Synopsis:

Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Revive Therapeutics named herein, including the promotion by the Company of Revive Therapeutics in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).